Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-531 phase 3 trial of selpercatinib versus physician's choice cabozantinib or vandetanib in RET-mutant advanced medullary thyroid cancer
MOH_2020-03-24_008796Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selpercatinib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by Eli Lilly and Company. Started Feb 2020; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on MOH_2020-03-24_008796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-24_008796.